The 'Toxic' Hormone That Just Broke Every Obesity Record

🩺 Get your personalized health plan: https://drstanfield.com/pages/roadmap 💊 Supplements I Take: https://drstanfield.com/pages/my-supplements 💊MicroVitamin+ (Pro) Powder: https://drstanfield.com/products/microvitamin-plus 💊MicroVitamin Standard Capsules: https://drstanfield.com/products/microvitamin Timestamps: 00:00 Glucagon's Role in Obesity and Diabetes 02:49 The Discovery of GLP-1 and GIP 04:44 Results of the New Retatrutide Trial 06:45 Side Effects of Retatrutide 08:59 The Importance of Protein Intake ✔️ X: https://x.com/BradStanfieldMD ✔️ Patreon: https://www.patreon.com/bradstanfieldmd Here are the links to the research papers referenced in the video: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average — TRIUMPH-4 press release https://pmc.ncbi.nlm.nih.gov/articles/PMC5805853/ — Glucagon discovery (Peptides 2018) https://journals.lww.com/jodb/fulltext/2023/11001/historical_perspectives_of_glucagon_s_discovery.4.aspx — Glucagon history (JODB 2023) https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.12958 — LY2409021 glucagon antagonist trial https://pmc.ncbi.nlm.nih.gov/articles/PMC4509428/ — GLP-1 receptor agonists review https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html — Ozempic FDA approval https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 — Semaglutide STEP 1 (NEJM 2021) https://pmc.ncbi.nlm.nih.gov/articles/PMC12507501/ — Tirzepatide dual agonist review https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 — SURMOUNT-1 tirzepatide (NEJM 2022) https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-achieved-157-weight-loss-adults-obesity-or — SURMOUNT-2 press release https://pmc.ncbi.nlm.nih.gov/articles/PMC3609580/ — GLP-1 + glucagon co-infusion https://insights.som.yale.edu/podcasts/health-veritas/ania-jastreboff-treating-obesity-without-shame — Jastreboff Yale podcast https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 — Retatrutide Phase 2 (NEJM 2023) https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html — TRANSCEND-T2D-1 press release https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-obesity-drug-falls-short-against-eli-lillys-copenhagen-trial-2026-02-23/ — Reuters: CagriSema vs Zepbound https://my.clevelandclinic.org/health/symptoms/24989-dysesthesia — Cleveland Clinic: dysesthesia https://www.usatoday.com/story/life/health-wellness/glp-1-cost/88513308007/ — USA Today: GLP-1 drug costs https://www.cbsnews.com/boston/news/blue-cross-blue-shield-massachusetts-weight-loss-glp1/ — BCBS Massachusetts drops GLP-1 coverage https://www.bmj.com/content/392/bmj-2025-085304 — Weight regain after stopping (BMJ 2025) Thumbnail by James Kelly Video edited by Troy Young Script by John Milliken The links above are affiliate links, so I receive a small commission every time you use them to purchase a product. The content contained in this video, and its accompanying description, is not intended to replace viewers’ relationships with their own medical practitioner. Always speak with your doctor regarding the content of this channel, and especially before using any products, services, or devices discussed on this channel.